Table 7 Patients and tumor characteristics of the selected studies Melanoma and Target Therapy
From: Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
a | |||||||||
Authors (year of publication) [reference] | N of pts underwent SBRT | Type of study | Primary tumor | N of mts underwent to SBRT | Type of Oligometases and organ involved | Median total dose (dose per fraction | BED | Systemic Therapy | Mts size (cm) |
Kotecha 2017 [45] | 191 (19 pts. had BRAF mutated tumorsa) | retrospective | melanoma | 793 (81 received BRAFi) | Brain | According to the RTOG protocol 90–05 | BRAFi | 1 | |
Wolf 2016 [39] | 80 (31 received BRAFi) | prospective | melanoma | Brain | |||||
Franceschini 2017 [44] | 31 (3 received BRAFi) | retrospective | melanoma | 38 | Extracranial (lung, liver, nodes) | 48 Gy (4) | >100Gy in 74% of pts | BRAFi | 39.6 cm3 (mean) |
Ahmed 2016 [40] | 96 (18 received BRAFi, 12 received BRAF/ MEKi) | retrospective | melanoma | 314 (103 received Targeted Therapy) | Brain | 24 Gy(1) | BRAFi or BRAF/ MEKi | 0.1 cm3 | |
Gaudy-Marqueste 2014 [41] | 30 | retrospective | melanoma | 263 | Brain | Range 20–28 Gy | Vemurafenib (26) or Dabrafenib (4) | N/A | |
Hecht 2018 [46] | 39 | retrospective | melanoma | Brain | Vemurafenib (23) or Dabrafenib (16) | ||||
Ly 2015 [42] | 52 (17 received BRAFi) | retrospective | melanoma | 198 (96 received BRAFi) | Brain | 20 Gy (1) | |||
Mastorakos 2018 [47] | 67 | retrospective | melanoma | Brain, extracranial mts. | According to RTOG 95–08 guidelines_ 19.2 Gy | 1.1 cm3 | |||
Patel 2017 [43] | 87 (15 received BRAFi) | retrospective | melanoma | 157 (32 received BRAFi) | Brain | 21 Gy | Vemurafenib (14) or Dabrafenib (1) | 0.12 cm3 | |
b | |||||||||
Authors (Year of Publication) [reference] | Local Control | Progression Free Survival | Overall Survival | Toxicity | |||||
Kotecha 2017 [45] | N.S. | N.S. | N.S. | N.S. | |||||
Wolf 2016 [39] | 94.6% | 3.9 mo | 13 mo (median)a Actuarial: 83% at 3 mo 65% at 6 mo 46% at 12 mo | No increase in hemorrage rates in SRS + BRAFi | |||||
Franceschini 2017 [44] | 96.6% at 12 mo 82.8% at 24 mo | 5.8 mo (median) Actuarial: 48.2% at 6 mo 18.5% at 12 mo 13.9% at 24 mo | 10.6 mo (median) Actuarial: 77% at 6 mo 41% at 12 mo 21% at 24 mo | Acute 1 G2 (pneumonia) Late 1 G2 pneumonia 1 G2 dyspnea 1 gastric ulceration | |||||
Ahmed 2016 [40] | 89% at 6 mo 83% at 12 mo | 3.4 mo (median) Actuarial(BRAF/MEKi) 58% at 6 mo 39% 1 t 12 mo Actuarial (BRAFi) 29% at 6 mo 12% at 12 mo | Actuarial (BRAF/MEKi) 83% at 6 mo 75% at 12 mo Actuarial (BRAFi) 71% at 6 mo 29% at 12 mo | 1 G2 headache 1 radionecrosis | |||||
Gaudy-Marqueste 2014 [41] | 24.8 weeks (median) | 20% of pts. presented neurological symptoms | |||||||
Hecht 2018 [46] | No difference in median values between Concomitant and Interrupted treatment | Concomitant BRAFi: 4.2 mo Interrupted BRAFi: 5.8 mo | Concomitant BRAFi: 7.3 mo Interrupted BRAFi: 9.8 mo | Radiation dermatits > G1: Concomitant BRAFI: 35% of pts. Interrupted BRAFi: 14%. | |||||
Ly 2015 [42] | 85% at 1 yr | 32.3% at 1 yr | 50.2% at 1 yr | Freedom from intratumoral hemmorrhage at 1 year: 39.3% | |||||
Mastorakos 2018 [47] | 23% local progression rate at 1 yr | 13 mo (median) Actuarial: 70.1% at 6 mo 52.2% at 12 mo 20.9% at 24 mo | 10.4% of pts. with Inttracranial hemmorhage | ||||||
Patel 2017 [43] | 3.3% LR at 1 yr | N.S. | 78.6% at 6 mo 64.3% at 12 mo | 8 pts. developed symptomatic RN | |||||